Introduction
Coronary heart disease is the leading cause of death in the United Kingdom. People with symptoms of coronary heart disease-such as angina pectoris-are at particularly high risk of death from coronary heart disease. It is estimated that, in a one year period, 1% of the population present with anginal symptoms to a general practitioner, 1 and within about one year of initial consultation, around one in 10 patients will either have a non-fatal myocardial infarction, or die from coronary causes.
2 Interventions for angina aim to reduce symptoms, increase functioning, and reduce the risk of myocardial infarction and death. As well as modification of lifestyle-such as stopping smoking and reducing weight-the mainstay of treatment of angina in general practice is the use of drugs-such as blockers, nitrates, calcium channel blockers, and aspirin. The Standing Medical Advisory Committee has also recommended that patients with angina who have high concentrations of total cholesterol or low density lipoprotein should be considered for cholesterol lowering medical treatment to prevent progression of coronary artery disease. 3 Patients are often referred for further investigations to assess the pattern and extent of the underlying coronary artery disease and other prognostic factors which determine severity of disease and the appropriateness of invasive procedures. There is evidence that United Kingdom referral rates vary widely. 4 5 The main invasive treatments are percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG). This paper examines the evidence for the eVectiveness and cost eVectiveness of medical treatment, CABG, and PTCA in patients with stable angina. It is based on a review commissioned by the National Health Service (NHS) health technology assessment programme, 6 which formed the basis for part of a recent EVective Health Care Bulletin 1997 vol 3. 
Methods
The review included randomised controlled trials of non-drug interventions and drug treatment (for which at least 6 months of follow up was required for inclusion). Medical treatments were included if they compared different classes of drug. Publications on clinical eVectiveness, and cost and cost eVectiveness were identified by a search of computerised databases. Details of the studies included can be found in the main systematic review (appendix). 
Results

MEDICAL TREATMENTS
Relief of symptoms
There are few long term comparisons of the eVectiveness of diVerent classes of drugs in relieving symptoms of angina. These studies show no major diVerences between the main classes of drug treatment. [8] [9] [10] [11] [12] [13] [14] [15] There is also no evidence that combination treatment is more eVective than monotherapy, 16 17 and no evidence of major treatment related diVerences in health related quality of life.
Secondary prevention of cardiac events
A meta-analysis has shown that antiplatelet drugs significantly reduce the incidence of myocardial infarction among patients with stable angina. 18 Antiplatelet treatment showed even greater reductions in the incidence of myocardial infarction, stroke, and vascular death in high risk patients-such as those with a history of myocardial infarction or stroke. There is no evidence that dipyridamole, used alone or in combination with aspirin, is more eVective than the cheaper option of aspirin alone (table 1) .
PTCA AND CABG COMPARED WITH MEDICAL TREATMENT
PTCA compared with medical treatment
Angioplasty is more eVective at relieving angina than medical treatments. 19 20 The advantages of PTCA are greatest in patients with more severe angina at baseline, and there seems to be little extra benefit for patients with few symptoms. The advantage of PTCA in relief of symptoms decreases over time, with little diVerence at 3 years, because of the high rate of restenosis after the initial procedure. 20 21 However, although PTCA can relieve symptoms in some groups of patients, it has not been shown to improve survival. The second randomised intervention treatment of angina (RITA-2) trial showed that PTCA was associated with an increased rate of adverse cardiac events (nonfatal myocardial infarction and death) compared with medical treatment, mainly due to early procedure related events (table 1) . 21 
CABG compared with medical treatment
Grafting improves symptoms of angina and other indicators of health related quality of life over 10 years compared with medical treatment, 22 although with greater procedure related risks of myocardial infarction or death. [23] [24] [25] The potential benefits of CABG in improving event free survival are therefore only likely to be realised in patients at higher risk of mortality from coronary heart disease. For example, a meta-analysis of seven randomised controlled trials showed that, although on average mortality was reduced in patients treated by CABG compared with those treated medically, this benefit was confined to higher risk patients (table 1) . 25 There was a nonsignificant trend towards greater mortality after CABG in lower risk patients.
There are no recent cost eVectiveness analyses of these alternatives; further evaluation of newer procedures such as minimally invasive CABG is also required.
PTCA COMPARED WITH CABG
A meta-analysis of eight randomised controlled trials comparing angioplasty with grafting found that at 1 year CABG was better at alleviating anginal symptoms in both single and multivessel disease than PTCA (table 1). 26 Angioplasty also had a higher rate of repeat intervention over the first year (34% v 3%; p<0.0001). There was substantial variation between the trials in the rate of repeat revascularisation after PTCA, ranging from 20% to >40%. This may reflect diVerences in patient populations, criteria for retreatment, and possible bias due to awareness of previous randomised procedures. No diVerence in mortality was found between the treatments although the sample of patients analysed was small. These results are consistent with those from a recent trial which found that prevalence of angina was higher at 5 years in patients with multivessel disease (21% v 15%, p=0.007), and revascularisation more likely after PTCA. 27 Angioplasty is not generally suitable for patients with left main coronary stenosis (and no existing bypass graft to protect it), and those with severe diVuse disease, 28 although it may still occasionally be carried out in these patients. The balance of risks and benefits generally favours use of PTCA for palliation in patients with less severe disease who are not getting adequate symptom relief on medical treatments, but there is little evidence that this will improve survival.
Relative costs
A United Kingdom cost-analysis found that the initial costs of PTCA and CABG were about £3000 and £6000 respectively in a nonLondon centre at 1993-4 prices. 29 However, because of its high reintervention rate the total NHS cost of PTCA rose to over 80% of the costs of CABG after 2 years. Publication of five year follow up data from this study is expected. 
Medical adjuncts to PTCA
A meta-analysis has reported that antiplatelet treatment significantly reduces the risk of myocardial infarction, stroke, and vascular death in patients after PTCA (table 1) . 18 Treatment with calcium channel blockers 30 and fish oils 31 may also reduce the risk of vascular occlusion although further evaluation in large trials is required. Several studies have investigated glycoprotein IIb/IIIa receptor blocking drugs. One of these, abciximab, has been found to reduce in hospital myocardial infarction and reintervention rates in patients at high risk of abrupt vessel closure. 32 Three year follow up from one study reported reductions in the need for reintervention and myocardial infarction after PTCA in patients at high risk of complications, although no overall reduction in mortality was found. 33 Trapidil, an antagonist of platelet derived growth factor, has been found to reduce restenosis and angina compared with aspirin at 6 months, 34 and an antioxidant, probucol, reduced restenosis rates and the need for repeat angioplasty compared with placebo at 6 months in patients with one or two vessel disease. 35 
Medical adjuncts to CABG
A meta-analysis of 20 trials found that antiplatelet treatment significantly reduced reocclusion rates compared with controls in patients after CABG (21% v 30%; table 1). 36 Lipid lowering treatment has also been found to reduce the risk of cardiac events and the need for revascularisation compared with placebo in patients with CABG. 37 
Cost eVectiveness of adjunctive medications in PTCA and CABG
A United States cost analysis found that abciximab reduced repeat admissions to hospital after PTCA but increased the overall mean cost per patient (including the cost of admission to hospital during the study period, 1991-2) by $293. 38 No studies have examined the cost eVectiveness of medical adjuncts to CABG.
It is unclear whether these newer adjunctive medical treatments are as eVective or cost eVective as cheaper alternatives-for example, aspirin. Larger, long term comparative studies would be useful to help identify optimal treatment after revascularisation.
NEWER TECHNOLOGIES: STENTS, LASER ANGIOPLASTY, AND ATHERECTOMY
Intracoronary stents
Stents involve placing a metal coil or tube within the stenosed artery and are used to prevent abrupt closure of the artery after PTCA and prevent longer term restenosis. The STRESS and BENESTENT studies reported that stents reduce the need for subsequent revascularisation. 39 40 In the STRESS study, angiographically-detected restenosis was lower in the stent group at 6 months. No significant diVerences in angina were found. 39 In BE-NESTENT, restenosis and the need for further PTCA were reduced in the stent group at 1 year. There were no diVerences in angina or need for CABG (table 2) . 40 A recent systematic review highlighted several problems with these trials. 41 Lack of blinding in the BENESTENT trial may have resulted in the investigators performing more revascularisations in patients receiving PTCA alone. In the STRESS study there were no differences in rates of restenosis when data were reanalysed on an intention to treat basis.
More recently, the SICCO trial found that stenting reduced the rates of angina, restenosis, and reocclusion at 6 months in the few patients with a chronically occluded coronary artery, 42 although the assessment of this outcome was unblinded. Another recent trial found patients with isolated stenosis of the left anterior descending coronary artery who received stents had lower rates of recurrence of angina and restenosis at 12 months. 43 However, the outcome assessment was unsystematic and unblinded. Although the initial studies of stents reported high vascular complication rates, this is likely to have been due to the use of an intensive anticoagulation regimen. This has since been replaced with aspirin and ticlopidine, which produce fewer complications. 44 Stents rapidly came into routine use before being fully evaluated, and around 30%-60% of PTCA procedures now involve stents. Clinical belief, based on practical experience, is that they are beneficial for patients. As stent technology has evolved rapidly, the results of earlier studies are now becoming outdated, and continuing evaluation of this rapidly diVusing technology is therefore essential. Several trials are due to be reported in the near future. 45 Laser angioplasty; directional and rotational atherectomy; radiotherapy Laser angioplasty, and directional and rotational coronary atherectomy are no more eVective than standard PTCA. [46] [47] [48] [49] [50] [51] Catheter based radiotherapy has been reported to reduce restenosis at six months after stent implantation, though the study may be too small to detect diVerences in clinical outcomes. 52 Further evaluation of this technology (and of newer procedures-such as minimally invasive CABG) is required.
Cost eVectiveness of intracoronary stents and atherectomy
Two economic evaluations have reported that stents increase overall costs at 1 year compared with standard PTCA. 53 54 One of these 53 reported that they were more cost eVective given the improved outcomes; however, many of the studies it was based on are now outdated, as some are >10 years old. Studies comparing PTCA with atherectomy suggest that atherectomy is more costly, and no more eVective. 48 55 56 No studies have examined the costs of laser angioplasty.
Conclusions
There is little evidence of important differences in the eVectiveness and cost eVectiveness of the principal classes of medical treatments for angina, used singly or in combination. The choice of medical treatment should, therefore, be based on the consideration of adverse effects and compliance, and on overall costs.
Both CABG and PTCA substantially improve symptoms of angina. Grafting improves survival in patients with severe disease and leads to less reintervention. However, PTCA is probably more useful as a palliative treatment in less severely ill patients whose symptoms are inadequately controlled by medical treatment, or other patients for whom surgery is not advisable. In those patients in whom both procedures are equally appropriate, patients' preferences for trade oVs between degree of symptom relief and speed of recovery may be the key factors in determining choice of treatment.
More recent approaches to revascularisation, such as stents, have not been reliably shown to be more cost eVective than standard PTCA or CABG; continuing evaluation is required, and the results of future trials need to be carefully appraised to determine the eVectiveness of stenting in angioplasty.
Several areas for further research were identified by the review, including assessment of the eVectiveness and cost eVectiveness of the new generation medical and non-medical adjuncts to PTCA and CABG; cost and cost eVectiveness of PTCA compared with medical treatment; and investigation of patients' treatment and health related preferences about stable angina. Further economic evaluations of alternative treatments for stable angina are also needed.
Finally, improvements in the appropriateness and equity of care may be achieved if regularly updated guidelines are developed to include agreed referral criteria for assessment of the pattern and extent of CHD. These should specify indications or thresholds for intervention, based on best available evidence, and take into account measures of disease severity or risk. Such guidance could also play a part in ensuring more cost eVective treatment.
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Mean age: 54 y 66% male. NYHA class: 1 4%, II 73%, III 23% Angina attack frequency and exercise tolerance showed no greater improvement with combination therapy than with sole agents at follow up.
Gapinski et al 1993 31
Meta-analysis of 7 RCTs of omega-3 fatty acids
Patients undergoing PTCA with restenosis defined using angiography or stress testing
Significant relation between restenosis and dose (p=0.03) For studies using angiography, absolute diVerence in restenosis rates=14% (95% CI: 3,25%) For studies using stress testing, absolute diVerence in restenosis rates=5% (95% CI: -4 to 14%)
